Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06257342
Active, not recruiting Observational

Physical Abilities of Teenagers With Familial Mediterranean Fever

NCT06257342 · tracked via the Priya Life Science France tracker
Sponsor
Véronique Hentgen
Phase
Observational
Started
2023-07-30
Last updated
2024-02-13

Condition(s) studied

Familial Mediterranean Fever

Investigational drug(s) / intervention(s)

6 minutes walk

6 minutes walk: A 6 minutes walk test

Study summary

Physical abilities of teenagers with familial Mediterranean fever

Eligibility

Sex
ALL
Min age
12 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with a clinical diagnosis of FMF according to the Tel-Hashomer criteria for whom a sports evaluation was offered during their bridging program * Age \>12 * Followed or having been followed in the pediatric department of the CH of Versailles * No opposition of the patient and his/her parent/legal guardian in case of a minor patient Exclusion Criteria: Expressed refusal of the patient and his/her parent/legal guardian to participate in the study and/or to use genetic data for research purposes

Primary outcome measure(s)

  • the maximum oxygen consumption (VO2max) estimated from the 6-minute walk test — 6 minutes
    Describe the maximum oxygen consumption (VO2max) estimated from the 6-minute walk test

Trial sites (1)

FacilityCityRegionStatus
CH de Versailles Le Chesnay France

Other trials for the same condition

Characterization of a Functional Test for Mediterranean Family Fever Screening - 2 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06257342 on ClinicalTrials.gov ↗ ← All trials in France